A Thyroid-Cancer-Specific Utility Index: Development and Valuation of the Thyroid Cancer Quality of Life Index.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: thyroid cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] TCQOLI is a psychometrically robust, thyroid-cancer-specific, preference-based measure with patient-anchored valuation, suitable for health-economic evaluations. This concise index supports comparative-effectiveness research in thyroid cancer and informs resource allocation across clinical and policy settings.
[BACKGROUND] Thyroid cancer survivors experience distinctive, persistent burdens that diminish health-related quality of life (HRQoL).
- 연구 설계 cross-sectional
APA
Cunningham CE, van Dijk S, et al. (2026). A Thyroid-Cancer-Specific Utility Index: Development and Valuation of the Thyroid Cancer Quality of Life Index.. Thyroid : official journal of the American Thyroid Association, 36(3), 278-290. https://doi.org/10.1177/10507256261425624
MLA
Cunningham CE, et al.. "A Thyroid-Cancer-Specific Utility Index: Development and Valuation of the Thyroid Cancer Quality of Life Index.." Thyroid : official journal of the American Thyroid Association, vol. 36, no. 3, 2026, pp. 278-290.
PMID
41735804 ↗
Abstract 한글 요약
[BACKGROUND] Thyroid cancer survivors experience distinctive, persistent burdens that diminish health-related quality of life (HRQoL). Utilities from patient preference-based measures are needed for quality-adjusted life-year estimation and decision-making. Generic instruments lack thyroid-specific content, limiting applicability in this population. We sought to develop a thyroid-cancer-specific utility measure, Thyroid Cancer Quality of Life Index (TCQOLI) to support clinical research, cost-effectiveness analyses, and policy applications.
[METHODS] We conducted a multicenter, multiphase, mixed-method, cross-sectional study. Phase 1 defined the TCQOLI domains and items using input from multidisciplinary experts and patients with thyroid cancer. Phase 2 evaluated the instrument via cognitive interviews ( = 50) and a mailed/phone-assisted psychometric survey in adults with thyroid cancer ( = 163), followed by confirmatory factor analysis (CFA) and reliability/validity analyses. Phase 3 valued health states in a separate sample ( = 103) using interviewer-administered visual analog scales (VAS; 0-100) and standard gamble (SG). Levels of morbidity in each health domain with VAS and SG were used for assessing preferences for three clinical marker states. We derived a weighted dead-to-full-health lower VAS anchor, estimated a VAS to SG power mapping solution to apply to the model overall, and constructed additive, multiplicative, and unweighted indices. Agreement of the indices with direct VAS was summarized by Pearson , mean absolute error (MAE), overall standard deviation (OSD) of differences, and intraclass correlation (ICC).
[RESULTS] Ten candidate domains were finalized; because one domain, reproduction concern, had the weakest psychometrics and the lowest model weight, the primary instrument uses nine domains (a 10-domain version was also evaluated). CFA supported a general HRQoL factor plus a voice/swallow factor with acceptable composite reliability and model fit. The instrument-level ceiling effect was low (3.8%) with no floor effect. The 9-domain additive multiattribute utility theory index correlated with direct VAS ( ≈ 0.74-0.75) and showed the best agreement. MAE/OSD was 0.045/0.095 after SG mapping and a good to excellent ICC of 0.74.
[CONCLUSIONS] TCQOLI is a psychometrically robust, thyroid-cancer-specific, preference-based measure with patient-anchored valuation, suitable for health-economic evaluations. This concise index supports comparative-effectiveness research in thyroid cancer and informs resource allocation across clinical and policy settings.
[METHODS] We conducted a multicenter, multiphase, mixed-method, cross-sectional study. Phase 1 defined the TCQOLI domains and items using input from multidisciplinary experts and patients with thyroid cancer. Phase 2 evaluated the instrument via cognitive interviews ( = 50) and a mailed/phone-assisted psychometric survey in adults with thyroid cancer ( = 163), followed by confirmatory factor analysis (CFA) and reliability/validity analyses. Phase 3 valued health states in a separate sample ( = 103) using interviewer-administered visual analog scales (VAS; 0-100) and standard gamble (SG). Levels of morbidity in each health domain with VAS and SG were used for assessing preferences for three clinical marker states. We derived a weighted dead-to-full-health lower VAS anchor, estimated a VAS to SG power mapping solution to apply to the model overall, and constructed additive, multiplicative, and unweighted indices. Agreement of the indices with direct VAS was summarized by Pearson , mean absolute error (MAE), overall standard deviation (OSD) of differences, and intraclass correlation (ICC).
[RESULTS] Ten candidate domains were finalized; because one domain, reproduction concern, had the weakest psychometrics and the lowest model weight, the primary instrument uses nine domains (a 10-domain version was also evaluated). CFA supported a general HRQoL factor plus a voice/swallow factor with acceptable composite reliability and model fit. The instrument-level ceiling effect was low (3.8%) with no floor effect. The 9-domain additive multiattribute utility theory index correlated with direct VAS ( ≈ 0.74-0.75) and showed the best agreement. MAE/OSD was 0.045/0.095 after SG mapping and a good to excellent ICC of 0.74.
[CONCLUSIONS] TCQOLI is a psychometrically robust, thyroid-cancer-specific, preference-based measure with patient-anchored valuation, suitable for health-economic evaluations. This concise index supports comparative-effectiveness research in thyroid cancer and informs resource allocation across clinical and policy settings.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.